REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 26-28, 2023, in New York, New York.
Management will participate in a fireside chat on Tuesday, September 26, 2023, at 9:20 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Lauren Musto
(781) 572-1147
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.90 |
| Daily Change: | 0.07 3.55 |
| Daily Volume: | 30,644 |
| Market Cap: | US$171.160M |
November 06, 2025 October 29, 2025 August 13, 2025 May 14, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load